

EMCDDA work programme for 1999

Final

Summary

The work programme of the EMCDDA for 1999 aims to pursue the progressive accomplishment of the priority objectives of its second three year work programme (1998 - 2000).

In this context, **during 1999 a special attention will be paid to the following targets :**

- **to further improve quality of epidemiological and demand reduction data collected by the Centre, (in particular the work on a set of harmonised indicators at EU scale)**
- **to consolidate the implementation of the EU Joint action on new synthetic drugs**
- **to strengthen the performance of the National Focal Points**
- **to develop a more structured partnership** with associated International Organisations (WHO, Pompidou Group, UNDCP, EUROPOL, INTERPOL, WCO) as well as with the European Institutions and Programmes and the associated neighbour countries, more specially the Central and Eastern European Countries in their pre accession phase
- **to strengthen the Centre's information technology and telematics systems**

Furthermore a special attention will be paid :

- **to strengthen the financial management and the accounting system of the Centre**, according to the requirements of the European Court of Auditors.

Budgetary effect

The present work programme indicates the estimated cost for its implementation. It takes into account the decision taken by the EMCDDA Management Board on the role and financing of National Focal Points (NFP), increasing the EMCDDA contribution for the implementation of the REITOX core-tasks and the REITOX specific projects.

The estimated costs for the implementation of the EMCDDA 1999 work programme (under title III of the EMCDDA 1999 budget) can be broken down as follows:

Activity	Estimated cost (EURO) for the EMCDDA Budget
<i>REITOX "Core tasks" (objective 3) *</i>	1.500.000 (100.000 x the 15 N.F.P.)
<i>REITOX "Specific projects" (objective 3) **</i>	290.000
<i>Activities under objectives 1, 2, 4, 5 and 6 **</i>	1.760.000
<i>EMCDDA SC and REITOX regular meetings</i>	100.000
TOTAL	3.650.000

* cost to be covered by the EMCDDA and the concerned EU MS, according to the following co-financing scheme:
50% EMCDDA (= 100.000) + 50% concerned MS (= 100.000)

** 100% of cost involved to be covered by EMCDDA budget

EMCDDA's Work programme for 1999

I. PRIORITY OBJECTIVES AND TARGETS

The work programme for 1999 of the EMCDDA aims to pursue the **progressive accomplishment of the priority objectives** of the second three year work programme of the EMCDDA (1998 - 2000):

PRIORITY OBJECTIVES FOR 1999

Consolidating and enhancing the achievements: Priority area n° 1 (Demand and demand reduction)

- A. COLLECTION AND ANALYSIS OF EXISTING DATA¹
AND
B. IMPROVEMENT OF DATA - COMPARISON METHODS¹

1. PRIORITY OBJECTIVE N° 1

Consolidating and improving THE EPIDEMIOLOGICAL AND DEMAND REDUCTION INFORMATION SYSTEMS on the basis of agreed sets of core data

- a) *Current trends and patterns: monitoring traditional illicit drugs*
b) *New trends: setting up and developing a mechanism for the information exchange, risk assessment and the control of new synthetic drugs*

2. PRIORITY OBJECTIVE N° 2

Improving and developing RELIABLE AND COMPARABLE METHODS, DATA SYSTEM AND KEY-INDICATORS

3. PRIORITY OBJECTIVE N° 3

Consolidating and enhancing THE REITOX NETWORK in accordance with the decisions taken by the Management Board of the EMCDDA on the role, the tasks and the financing of the National focal points.

C. DISSEMINATION OF DATA¹

4. PRIORITY OBJECTIVE N° 4

Improving the quality of the ANNUAL REPORT ON THE STATE OF THE DRUGS PROBLEM in the EU, the visibility of the activity of the EMCDDA and REITOX and the DISSEMINATION OF THE INFORMATION COLLECTED AND PRODUCED by the EMCDDA

D. CO-OPERATION WITH EUROPEAN AND INTERNATIONAL BODIES AND ORGANISATIONS AND WITH NON-COMMUNITY COUNTRIES¹

5. PRIORITY OBJECTIVE N° 5

Developing STRUCTURED CO-OPERATION WITH THE INTERNATIONAL PARTNERS OF THE EMCDDA and ensuring synergies and complementarity with the EU programmes and activities, avoiding any duplication of work

Developing the achievements: Priority area n° 2 (National and Community strategies and policies)

A. COLLECTION AND ANALYSIS OF EXISTING DATA¹

6. PRIORITY OBJECTIVE N° 6

Gradually developing tools and methodologies towards the COMPARISON OF INTERVENTIONS, LEGISLATION, STRATEGIES AND POLICIES IN THE EU (including cost effectiveness evaluation)

¹ Fundamental tasks of the EMCDDA, in accordance with article 2 of the founding regulation (EEC) 302/93.

In particular the EMCDDA, in accordance with its 1998-2000 work programme, will progressively carry out its tasks in the other 4 priority areas defined in its funding regulation (taking into account that during the first three-year period special attention has been given to the first priority area: demand and demand reduction), consolidating and developing the activities carried out in 1998 and starting some new projects.

In this context, according to the provision of the EMCDDA's three-year work programme for 1998-2000, **during 1999 a special attention will be paid to the following targets :**

- **to further improve quality of epidemiological and demand reduction data collected by the Centre.** In particular the work on a set of harmonised indicators at EU scale, after a necessary feasibility phase, will have to become fully operational, with the strong involvement and commitment of the Member States and the National Focal Points;
- **to consolidate the implementation of the EU Joint action on new synthetic drugs**, developing structured working methods and mechanisms for information exchange and risk assessment;
- **to strengthen the performance of the National Focal Points** in relation to their core tasks (information map, annual report, core-indicators, EDDRA, implementation of the Joint Action on new synthetic drugs) and to enhance their relationship with the Centre in Lisbon and their role in the implementation of the EMCDDA's work programme, allowing them also to gradually broaden the scope of their work to potential core-tasks.
- **to develop a more structured partnership** with associated International Organisations (WHO, Pompidou Group, UNDCP, EUROPOL, INTERPOL, WCO) as well as with the European Institutions and Programmes and the associated neighbour countries, more specially the Central and Eastern European Countries in their pre accession phase; this partnership should be defined, where appropriate, in "memoranda of understanding" and concretised in joint action programmes on the basis of mutual interest, mechanisms for co-operation, exchange of information, concerted participation to the EMCDDA activities;
- **to strengthen the Centre's information technology and telematics systems** (EMCDDA-REITOX electronic network, demand reduction information systems, REITOX "virtual library", database applications, including the technical development of the pilot-project on legal texts EMCDDA web-site), particularly in order to improve the EMCDDA production and dissemination of information and publication.

Furthermore a special attention will be paid :

- **to strengthen the financial management and the accounting system of the Centre**, according to the requirements of the European Court of Auditors., in order to step up the overall operational capacity of the EMCDDA.

II. BUDGETARY IMPLICATIONS

The present work programme indicates below the estimated cost for its implementation. It takes into account the decision taken by the EMCDDA Management Board on the role and financing of National Focal Points (NFP), increasing the EMCDDA contribution for the implementation of the REITOX core-tasks and the REITOX specific projects.

The estimated costs for the implementation of the EMCDDA 1999 work programme (under title III of the EMCDDA 1999 budget) can be broken down as follows:

Activity	Estimated cost (EURO) for the EMCDDA Budget
<i>REITOX "Core tasks" (objective 3) *</i>	1.500.000 (100.000 x the 15 N.F.P.)
<i>REITOX "Specific projects" (objective 3) **</i>	290.000
<i>Activities under objectives 1, 2, 4, 5 and 6 **</i>	1.760.000
<i>EMCDDA SC and REITOX regular meetings</i>	100.000
<i>TOTAL</i>	3.650.000

* cost to be covered by the EMCDDA and the concerned EU MS, according to the following co-financing scheme:
50% EMCDDA (= 100.000) + 50% concerned MS (= 100.000)

** 100% of cost involved to be covered by EMCDDA budget

The EMCDDA budget for 1999 will provide for the resources required to carry out the implementation of the present work programme.

The specific activities and projects to be implemented within the framework of the 1999 work programme of the EMCDDA are set out below.

**1999 ANNUAL REPORT ON
THE STATE OF THE DRUGS PROBLEM
IN THE EUROPEAN UNION**

a) Structure and contents

In order to follow most of the suggestions contained in David Turner's *Evaluation Report on the 1997 Annual Report on the State of the Drugs Problem in the European Union* and in line with the decisions taken at the 13th meeting of the EMCDDA's Management Board (2-3 July 1998), the 1999 edition of the publication will be marked by a strong modification in relation to the structure adopted for the first reports. The Report will no longer, carry two main sections, but only one relating to information on the situation of drugs. This means that data on anti-drug strategies and policies will not make part of this edition of the Annual Report.

To provide its main audience, the policy-makers, with reliable and comparable data needed to address the drugs subject, the 1999 *Annual Report* will consist of two different volumes, an abridged and an extended version (the abridged version will contain about 30 pages, will be published in all the EU languages and be available on the EMCDDA's web site. On the contrary, the extended version will have about 90 pages and will be published in one language only (English). Both versions will be published simultaneously.

The 1999 *Report* will, therefore, have a totally new structure with three core chapters, as follows:

Chapter 1 - New trends and developments in drug misuse in the EU;

Chapter 2 - Established responses to drug misuse in the EU (maximum of three specific subjects);

Chapter 3 - Patterns and prevalence of drug misuse and related problems in the EU;

Annexes

Annex 1: Key-word index

Annex 2: Glossary

Annex 3: List of the EMCDDA publications

b) Schedule

Experience in the preparation of the previous editions of the report shows that collection of data at national level and transmission of treated data to the EMCDDA, takes no less than the first quarter of each year. Thus, despite an earlier and clearer definition of guidelines for contributing to this year's *Annual Report* sent to the NFPs, the schedule to be followed in its preparation will have to take into consideration these difficulties and continue to establish **31 March 1999** as the deadline for information to be sent to the EMCDDA.

Schedule

		Schedule 1999 Report
Phase 1	Providing the Focal Points with guidelines for data collection	15 October 1998
Phase 2	Preparation of contributions to the <i>Report</i> and transmission of treated data to the Centre	16 October – 28 February 1999
Phase 3	Dialogue between the Centre and source partners to complement the material sent	1 January – 31 March 1999
Phase 4	Writing up of first draft	1 – 30 April 1999
Phase 5	Editing	1 – 31 May 1999
Phase 6	Consultation with Management Board, Scientific Committee and NFPs; finalising editorial work	1 – 30 June 1999
Phase 7	Layout + Translations	1 July – 15 August 1999
Phase 8	Printing	16 August – 15 September 1999*
Phase 9	Launch and distribution	22 September 1999

* Members of the Management Board will receive copies about two weeks before the launch.

- Subject: Criteria for:**
- (a) deciding whether projects should be included under Reitox or the Centre's budget line,**
 - (b) selecting NFPs to administer and co-ordinate projects under Reitox budget line.**

(a) deciding whether projects should be included under Reitox or the Centre's budget line

These criteria should include

- (1) Role of the NFPs: Does the project involve a core task of the NFPs and are the focal points necessarily the key partners?
- (2) Market conditions: Is an open tendering procedure appropriate (especially in light of answer to point 1 on role of NFPs)?
- (3) Value for money: What is the most efficient and effective way of implementing and administering the project?

(b) selecting NFPs to administer and co-ordinate projects under Reitox budget line.

These criteria should include:

- (1) Professional scientific/technical expertise and experience in the area concerned
- (2) Administrative infrastructure and legal possibilities to receive and administer project involving other Member States
- (3) Technical and human capacity to network effectively with other NFPs and partners on the topic concerned
- (4) Cost and cost-effectiveness
- (5) A reasonable geographical distribution and equitable balance between NFPs, taking account of the need to ensure quality and cost-effectiveness.